Proton pump inhibitors: important information for cardiologists

Thromboembolic disorders occupy an important place in the structure of cardiovascular pathologies. Anticoagulants and antiplatelet agents proved to be the most efficient preventive medications for this group of patients, they enable reduction of the risk for both primary and secondary thromboembolic complications. However, their main shortcoming is the high potential of serious adverse events, basically related to gastrointestinal tract. That’s why, to prevent stress ulcers and bleedings in these patients, administration of antiplatelet agents, thrombolysis and heparin therapy is obligatory combined with the proton pump inhibitors. The authors presented data of evidence‑based medicine regarding one of the proton pump inhibitors, Ezolong, that contains esomeprazole (branded generic of Organosyn company). This combined medication is a modern formulation with the improved properties and more prolonged and predictable effect. Apart from its high protective efficacy, Ezolong is well tolerated, which is explained by the peculiarities of its pharmacodynamics and pharmacokinetics. Based on the complex of its clinical effects and safety profile, it is the drug of choice for patients with cardiovascular diseases. Ezolong is marketed in various formulations. Availability of its injectable formulation allows to achieve a quick intake of the active substance into the body, which is important for the therapy of acute pathologies and in case of impossibility of oral administration of the drug. Capsulated Ezolong provides easy administration, dosing accuracy, high adherence to the therapy of patients receiving outpatient treatment.